Loading
Economic and Financial Impacts of Cancer / Ai in Cancer Detection / Lymphoma Diagnosis and Treatment · Journal article
Haematologica · August 13, 2026
A consensus or society position rather than new primary data.
This White Paper from the Global Lymphoma Registry Alliance proposes a strategic roadmap for establishing international collaboration, data harmonization, and automated integration of lymphoma registries to address gaps in real-world data collection and evidence generation. The document emphasizes the need for overcoming legal and privacy barriers to enable safer data sharing and facilitate collaboration among stakeholders (patients, policy-makers, regulatory authorities, and industry) to improve lymphoma outcomes globally.
Journal article. Lymphoma patients globally, through proposed registry network and stakeholder collaborations.
Lymphoma registries can contribute significantly to addressing gaps in understanding practice variation and provide evidence for health technology assessments Robust real-world data collection is needed to address challenges posed by evolving diagnostic classification and fast-paced therapy development Technologies for safer data sharing are already available, but legal frameworks and privacy concerns are not keeping pace with their intended purpose
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and researchers should view this as an agenda-setting document intended to catalyse international infrastructure development for real-world evidence generation in lymphoma. Implementation of these recommendations may improve trial contextualization and support external comparator cohorts, but the document itself reports no clinical outcome data.
A White Paper outlining strategic recommendations and a roadmap for international registry collaboration in lymphoma, not reporting original research findings or clinical trial data.
Clinicians and researchers should view this as an agenda-setting document intended to catalyse international infrastructure development for real-world evidence generation in lymphoma. Implementation of these recommendations may improve trial contextualization and support external comparator cohorts, but the document itself reports no clinical outcome data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Lymphomas comprise a complex and heterogeneous group of malignancies which pose challenges in understanding their epidemiology, pathobiology, treatment responses and long-term outcomes. Evolving diagnostic classification and fast-paced therapy development compound these challenges. Robust real-world data (RWD) collection and analysis using clinical registries can contribute significantly to address gaps in understanding of practice variation and provide evidence for health technology assessments. However, to maximize the impact of lymphoma registries, and those in other diseases, there is a compelling need for global collaboration, data harmonization and automated integration between registries and other large datasets. Technologies that enable safer data sharing are already available, but historical legal frameworks and evolving privacy concerns are not keeping pace, undermining their intended purpose and limiting the full potential of available high-quality RWD to improve patient care. This White Paper written by the Global Lymphoma Registry Alliance (LyRA) discusses the importance and value of lymphoma registries for different stakeholders as well as benefits of forming a global alliance of the registry network. An alliance such as LyRA serves both academic endeavors and public interest through collaboration between patient and community organizations, policy-makers, regulatory authorities, industry and others seeking to use RWD. Bringing these stakeholders together and raising awareness more broadly will facilitate timely clinical trial result contextualization and innovation in public-private collaborations on novel trial emulations and designs, including external comparator cohorts. The LyRA leadership propose strategies for overcoming barriers to facilitate these key collaborations towards improving patient outcomes on a global scale.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.